Eli Lilly's new Alzheimer's treatment has shown effectiveness in some patients, according to a U.S. advisory panel. The drug, which aims to prevent and slow the progression of Alzheimer's disease, has led to a 3.5% rally in Lilly's stock. Experts highlight its potential as a disease-modifying drug, with future treatments likely to involve combination therapy and precision medicine driven by biomarkers. The treatment is moving closer to securing FDA approval, with discussions ongoing about its broader implications. Clinical trials are underway, and BMO Capital's managing director Evan Seigerman has discussed the developments.
A new drug could slow the progression of Alzheimer's, writes @lisamjarvis. But there's a catch (and it's not the cost) https://t.co/fm19IphYH9
$LLY gets closer to securing FDA approval for new Alzheimer's treatment. BMO Capital managing director Evan Seigerman discusses: https://t.co/qWT2WoxBjf
"It's the first time we are having a disease-modifying drug that could lead to prevention," says @a_hfillit on Eli Lilly's new Alzheimer's drug. "I think the future will lie just like in cancer, in combination therapy with precision medicine driven by biomarkers." https://t.co/TlPaz4jXoY
$LLY Lilly Rallies After Better Than Expected Panel Vote: Street Wrap (Bloomberg) - ind. +3.5% https://t.co/8PHu36T6Ue
#EliLilly’s treatment for #Alzheimer’s disease works in at least some patients, says U.S. advisory panel.
New drugs could stop help prevent Alzheimer's—if they prove effective in these clinical trials [Sponsored by @DavosAlzheimers] https://t.co/v7iOJdRQuj